Oakley Capital Acquires Majority Stake in vitroconnect

Oakley Capital Acquires Majority Stake in XTEL from Bain Capital and SilverTree Equity

May 26, 2026

Software

Oakley Capital is acquiring a majority stake in XTEL, a revenue management and trade promotion software platform for consumer packaged goods (CPG) companies. The deal is being purchased from existing shareholders Bain Capital and SilverTree Equity, with XTEL continuing to be led by CEO Rob Mullen.

Oakley Capital Invests in ProductLife Group

May 28, 2024

Pharmaceuticals

Oakley Capital Fund V is investing in ProductLife Group, a European provider of outsourced development, regulatory and compliance services to the life sciences industry. Oakley will partner with management and reinvesting shareholder 21 Invest to support international expansion, accelerate AI-driven technology enablement, and pursue a buy-and-build strategy.

Oakley Capital Origin Fund I Acquires Majority Stake in Horizons Optical

March 18, 2024

Medical Devices

Oakley Capital Origin Fund I is acquiring a majority stake in Horizons Optical from Sherpa Capital, with CEO Santiago Soler retaining a significant share and remaining CEO. Horizons, founded in Barcelona in 2017, provides proprietary medical software and scanning equipment used by independent laboratories and opticians to manufacture premium bespoke spectacle lenses; Oakley will support international expansion and R&D, and invest in Sales & Marketing to accelerate growth.

Oakley Capital Origin Fund Invests in Vice Golf (Vice Sporting Goods GmbH)

May 6, 2022

Consumer Products

Oakley Capital Origin Fund is investing in Vice Sporting Goods GmbH (trading as Vice Golf), a digitally-native Munich-based golf brand known for DTC premium golf balls and accessories. The investment will support Vice Golf's international expansion, product diversification (including apparel collaborations) and acceleration of its direct-to-consumer growth.

BroadOak Capital Partners Invests Growth Capital in PhenoVista Biosciences

January 18, 2022

Biotechnology

PhenoVista Biosciences, a San Diego–based provider of high-content, imaging-based phenotypic assay services, raised growth capital from BroadOak Capital Partners. The funding will be used to accelerate development of complex biological models (e.g., blood–brain barrier, neurodegenerative disease platforms) and expand PhenoVista's assay and data-analysis capabilities.

Oakley Capital Fund IV and CVC Growth Acquire Majority Stake in TechInsights

December 15, 2021

Data & Analytics

Oakley Capital Fund III has agreed to sell its stake in TechInsights, with Oakley Capital Fund IV acquiring a majority stake alongside CVC Growth Funds. The transaction provides an exit for Fund III while delivering follow-on investment to support TechInsights' shift to subscription revenues and a multi-year expansion programme under CEO Gavin Carter.